Is testing for Legionella pneumophila appropriate and could it impact treatment?
Researchers assessed whether there was geographic variation in racial disparity in influenza and pneumonia.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
Researchers assessed glucocorticoid maintenance dose and treatment duration on outcomes in patients with ANCA-associated vasculitis.
Investigators conducted the PlasmAr trial to evaluate the safety and efficacy of convalescent plasma in the treatment of SARS-CoV-2 pneumonia.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
Cadmium burden is associated with increased mortality from influenza or pneumonia in US adults.
Clinical status, mortality did not differ for convalescent plasma versus placebo in adults with severe COVID-19 pneumonia.
Researchers investigated the effects of ILI on pneumococcal carriage in community-dwelling older adults.
Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
Researchers compared the efficacy and safety of cefiderocol vs high-dose, extended-infusion meropenem for adults with nosocomial pneumonia.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
The effect of appropriate antimicrobial therapy on 14-day mortality in patients severely ill with Acinetobacter baumannii bacteremic pneumonia was assessed, taking risk factors, patient demographics, and clinical characteristics into account.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
Study authors assessed pneumococcal urinary antigen testing’s use in identifying patients for broad-spectrum antibiotic de-escalation, providing an opportunity for improved antimicrobial stewardship.
Researchers linked the use of 2 hypertension drug classes to lower mortality for those hospitalized with flu and pneumonia.
Pneumomediastinum, although a rare phenomenon, is more prevalent in patients with COVID-19 compared with historical patients with adult respiratory distress syndrome.
Patients with severe COVID-19 pneumonia had improved prognosis after receiving a short course of methyl-prednisolone pulses during the second week of disease.
Approximately 7% of pneumonia cases acquired in the intensive care unit can be classified as
Staphylococcus aureus intensive care unit pneumonia.